BIOENVISION INC·4

Dec 23, 11:47 AM ET

BIOENVISION INC 4

4 · BIOENVISION INC · Filed Dec 23, 2004

Insider Transaction Report

Form 4
Period: 2004-12-21
Transactions
  • Sale

    Common Stock

    2004-12-21$8.44/sh1,160$9,790405,144 total(indirect: See Footnotes)
  • Sale

    Common Stock

    2004-12-21$8.43/sh209$1,762406,304 total(indirect: See Footnotes)
  • Sale

    Common Stock

    2004-12-21$8.50/sh3,655$31,068392,186 total(indirect: See Footnotes)
  • Sale

    Common Stock

    2004-12-21$8.41/sh316$2,658410,721 total(indirect: See Footnotes)
  • Sale

    Common Stock

    2004-12-21$8.48/sh35$297395,876 total(indirect: See Footnotes)
  • Sale

    Common Stock

    2004-12-21$8.46/sh1,621$13,714397,059 total(indirect: See Footnotes)
  • Sale

    Common Stock

    2004-12-21$8.53/sh52$444390,386 total(indirect: See Footnotes)
  • Sale

    Common Stock, $0.001 par value ("Common Stock")

    2004-12-21$8.40/sh21,172$177,845411,037 total(indirect: See Footnotes)
  • Sale

    Common Stock

    2004-12-21$8.52/sh18$153390,438 total(indirect: See Footnotes)
  • Sale

    Common Stock

    2004-12-21$8.42/sh4,208$35,431406,513 total(indirect: See Footnotes)
  • Sale

    Common Stock

    2004-12-21$8.47/sh1,148$9,724395,911 total(indirect: See Footnotes)
  • Sale

    Common Stock

    2004-12-21$8.45/sh6,464$54,621398,680 total(indirect: See Footnotes)
  • Sale

    Common Stock

    2004-12-21$8.51/sh1,730$14,722390,456 total(indirect: See Footnotes)
Footnotes (4)
  • [F1]These shares sold were held by Perseus-Soros Partners, LLC, a Delaware limited liability company ("Perseus-Soros Partners").
  • [F2]These securities reported herein are held for the account of Perseus-Soros BioPharmaceutical Fund, LP, a Delaware limited partnership ("Perseus-Soros") and Perseus-Soros Partners. Perseus-Soros Partners is the general partner of Perseus-Soros. Perseus BioTech Fund Partners, LLC, a Delaware limited liability company ("Perseus Partners") and SFM Participation, L.P., a Delaware limited partnership ("SFM Participation"), are the managing members of Perseus-Soros Partners. Perseus-Soros Partners, Perseus Partners, SFM Participation and SFM AH LLC may be deemed to beneficially own the 375,044 shares directly beneficially owned by Perseus-Soros after the transactions reported herein and in the other Form 4's filed by the reporting persons on December 23, 2004.
  • [F3]SFM AH LLC, a Delaware limited liability company ("SFM AH"), is the general partner of SFM Participation.
  • [F4]Pursuant to Rule 16a-1(a)(2)(ii)(B) under the Securities Exchange Act of 1934, as amended (the "Act"), Perseus-Soros Partners, Perseus Partners, SFM Participation and SFM AH are deemed to be beneficial owners of the shares beneficially owned by Perseus-Soros or Perseus-Soros Partners only to the extent of the greater of its respective direct or indirect interest in the profits or capital account of Perseus-Soros or Perseus-Soros Partners. Pursuant to Rule 16a-1(a)(4) under the Act, this filing shall not be deemed an admission that Perseus-Soros Partners, Perseus Partners, SFM Participation or SFM AH is, for purposes of Section 16 of the Act or otherwise, the beneficial owner of any securities owned by Perseus-Soros or Perseus-Soros Partners in excess of such amount.

Documents

1 file
  • 4
    form4-pspllc122104_bioex.xmlPrimary

    FORM 4